Trial Profile
A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs MAK 683 (Primary)
- Indications Carcinoma; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Ovarian cancer; Prostate cancer; Sarcoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 22 Feb 2024 This trial has been discontinued in Spain, according to European Clinical Trials Database record.
- 29 Dec 2023 This trial has been suspended in Italy.
- 12 Sep 2023 This trial has been completed in Germany, according to European Clinical Trials Database record.